About Morphic Holding, Inc. (MORF) — Dividend Analysis 2026
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Is MORF a good dividend investment in 2026?
MORF offers a 3.51% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
MORF DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your MORF portfolio grows to $6.31M vs $3.5K without reinvestment. This is the compound interest effect in action.
MORF dividend growth history & forecast
MORF has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 3.51%.
Company generates negative FCF ($-114M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.2B → -0.1B → -0.1B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 MORF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MORF.
Gross yield
3.51%
Tax rate
15.00%
After-tax yield
2.98%
Real yield (−CPI)
0.18%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
3.51%
0.71%
$351 / yr
🇺🇸 US Taxable (15%) ✓
15%
2.98%
0.18%
$298 / yr
🇺🇸 US Taxable (20%)
20%
2.81%
0.01%
$281 / yr
🇬🇧 UK ISA
0%
3.51%
0.71%
$351 / yr
🇬🇧 UK Taxable
8.75%
3.20%
0.40%
$320 / yr
🇨🇦 TFSA
0%
3.51%
0.71%
$351 / yr
🇨🇦 CA Taxable
25%
2.63%
-0.17%
$263 / yr
🇦🇺 Super (pension)
15%
2.98%
0.18%
$298 / yr
🇦🇺 AU Taxable
30%
2.46%
-0.34%
$246 / yr
🇩🇪 DE Taxable
26.375%
2.58%
-0.22%
$258 / yr
🇫🇷 FR Taxable
30%
2.46%
-0.34%
$246 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MORF Income Goal & Break-Even
Dividend Break-Even
34yr
Years for dividends to fully repay your MORF investment of $56.99/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$2.67M
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$2.67M
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in MORF for:
Shares needed
14,118
Capital required
$804,585
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MORF Dividend Payment Schedule
MORF pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 MORF vs Healthcare Benchmarks
How MORF compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+0.71% vs sectorBetter
MORF
3.51%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
MORF
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
MORF
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MORF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MORF Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Edwards Martin
director
D-Return
2024-08-16
2,376
$0.00
—
Edwards Martin
director
D-Return
2024-08-16
17,550
$24.49
$429.8K
Edwards Martin
director
D-Return
2024-08-16
12,535
$56.47
$707.9K
Edwards Martin
director
D-Return
2024-08-16
23,168
$30.52
$707.1K
Edwards Martin
director
D-Return
2024-08-16
9,996
$64.79
$647.6K
Edwards Martin
director
D-Return
2024-08-16
24,000
$31.00
$744.0K
SLATTERY JOSEPH P
director
D-Return
2024-08-16
12,000
$22.96
$275.5K
SLATTERY JOSEPH P
director
D-Return
2024-08-16
12,535
$56.47
$707.9K
SLATTERY JOSEPH P
director
D-Return
2024-08-16
24,000
$15.00
$360.0K
SLATTERY JOSEPH P
director
D-Return
2024-08-16
9,615
$64.79
$623.0K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🎯
Analyst Price Target
Wall Street consensus
Current Price
$56.99
Analyst Target
$57.00
Upside / Downside
+0.0%
Range
$57.00 – $57.00
💡 If MORF reaches the analyst target of $57.00, investors buying today at $56.99 would see an effective yield of 3.51% on shares purchased at target price — vs 3.51% at current price.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
🔬
Financial Health Scores
Altman Z-Score
60.85
✅ Safe Zone — low bankruptcy risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
2/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MORF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →